CIRM awards Salk Institute $10.8M grant to develop stem-cell based therapy for Lou Gehrig's Disease

Oct 29 2009

The Salk Institute has been awarded a $10.8 million grant by the California Institute for Regenerative Medicine (CIRM) for translational research focusing on developing a novel stem-cell based therapy for Amyotrophic Lateral Sclerosis (ALS) - or Lou Gehrig's Disease.

Sam Pfaff, Ph.D., a professor in the Salk's Gene Expression Laboratory and an investigator for the Howard Hughes Medical Institute, will lead the group of researchers who will work on the four-year project announced today as part of the $250 million CIRM Disease Team Award.

It marks the first CIRM funding explicitly expected to result in FDA approval for clinical trials. The grants were given to multidisciplinary teams of basic scientists, clinicians and industry in collaboration with two international partners, the Medical Research Council, UK, and the Cancer Stem Cell Consortium, Canada.

ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. When motor neurons die, the ability of the brain to initiate and control muscle movement is lost. The progressive degeneration of motor neurons in ALS eventually leads to paralysis and death.

The research team, which includes co-principal investigators Drs. Larry Goldstein and Don Cleveland, both of UCSD, will focus on astrocytes, the star-shaped support cells that provide nutrients for nearby motor neurons.

Working with six different lines of human embryonic stem cells (hESC), Pfaff and the team of researchers will grow clinical-grade astrocyte precursor cells and identify the line that is best suited for implantation in laboratory models.
They hypothesize that the transplanted human astrocyte precursors (hAP) will mature into astrocytes in vivo and provide support for diseased spinal motor neurons. Astrocytes are also capable of clearing excess neurotoxic glutamate and could thereby slow or halt the progression of ALS by preventing motor neuron degeneration.

Once the astrocyte precursors are tested for efficacy and safety to minimize the possibility of tumorigenesis, the next step will be to move forward with human clinical trials after approval by the FDA, says Pfaff.

"This team grant is a natural fit for San Diego because it capitalizes on the strength of neuromuscular disease research from the local scientific community," says Pfaff. "The standard has been set very high on this project because we are aiming to grow a safe population of astrocytes that can be introduced into patients. Our success will be measured by whether it will help extend the lives of patients suffering from ALS."

CIRM President Alan Trounson said the pace of the Disease Team projects stands in contrast to the decade or more that's usually required to reach clinical trials. "Scientists have talked for years about the need to find ways to speed the pace of discovery," he said. "By encouraging applicants to form teams composed of the best researchers from around the world we think CIRM will set a new standard for how translational research should be funded."

SOURCE The Salk Institute for Biological Studies